ONWARD1
57 evidence topics · 14 sources
Objective
Objective and questions in the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2024-07-25” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-09-19” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-11-20” (opens the source at this quote in a new tab)
“First Posted 2024-09-19” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-28” (opens the source at this quote in a new tab)
Completion dates estimated at registration, September 2024, superseded in June 2025
Results posting status and certification date in the ClinicalTrials.gov record
Countries of trial sites in the ClinicalTrials.gov record
| Country | First site listed for the country in the record |
|---|---|
| United States | “Phoenix, Arizona, United States, 85032” |
| Australia | “Kogarah, New South Wales, Australia, 2217” |
| Bulgaria | “Gabrovo, Bulgaria, 5300” |
| Canada | “Edmonton, Alberta, Canada, T5J 3S9” |
| Czechia | “Kutná Hora, Czechia, 28401” |
| Germany | “Tübingen, Baden-Wurttemberg, Germany, 72070” |
| Japan | “Fukuoka, Fukuoka-shi, Japan, 814-0180” |
| Poland | “Gdansk, Poland, 80-546” |
| Portugal | “Lisbon, Portugal, 1998-018” |
| South Korea | “Busan, South Korea, 49241” |
Country removed from the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Removed location countries (removedCountries) | “Belgium” |
Countries listed for ESK-001-016 and enrollment from Japan in the topline webcast presentation
Enrollment period and number of sites across ONWARD1 and ONWARD2
Study design
Design in the ClinicalTrials.gov record
“Primary Purpose : Treatment” (opens the source at this quote in a new tab)
“Allocation : Randomized” (opens the source at this quote in a new tab)
“Interventional Model : Parallel Assignment” (opens the source at this quote in a new tab)
“Masking : Quadruple” (opens the source at this quote in a new tab)
Parallel 24-week design of ONWARD1 and ONWARD2
Replicate design of ONWARD1 and ONWARD2
Placebo rollover to envudeucitinib at week 16 and treatment periods in the design schematic
Eligibility for the ONWARD3 long-term extension after week 24
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |
Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Participants with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |
Washout periods and prior treatment response in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |
Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in November 2024
Cardiac, infection, and laboratory exclusion criteria in the ClinicalTrials.gov record
Malignancy, vaccination, surgery, and psychiatric exclusion criteria in the ClinicalTrials.gov record
Key inclusion and exclusion criteria for ONWARD1 and ONWARD2 in the topline webcast presentation
“Total body weight >40 kg (88 lb )” (opens the source at this quote in a new tab)
“Plaques covering ≥10% of BSA at Screening and Day 1” (opens the source at this quote in a new tab)
“PASI ≥12 at Screening and Day 1” (opens the source at this quote in a new tab)
“sPGA ≥3 at Screening and Day 1” (opens the source at this quote in a new tab)
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Quoted record |
|---|---|
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |
Dose and randomization ratio across ONWARD1 and ONWARD2
No fasting requirement in ONWARD1 and ONWARD2
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Primary outcome in the ClinicalTrials.gov record
Secondary outcomes in the ClinicalTrials.gov record
Planned co-primary endpoints of ONWARD1 and ONWARD2
Co-primary, key secondary, and safety endpoints of ONWARD1 and ONWARD2 in the congress poster
Definitions of PASI and sPGA response thresholds in the congress presentation
Regulatory guidance on PASI as a primary endpoint and its pairing with a global score
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Planned enrollment at registration
Planned enrollment of approximately 840 participants per trial
Description of analysis sets
Intention-to-treat analysis of response endpoints in ONWARD1 and ONWARD2
Mixed model for repeated measures for itch in ONWARD1 and ONWARD2
Pooled safety analysis population of ONWARD1 and ONWARD2
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD1
| Characteristic | Envudeucitinib 40 mg BID, n = 459 | Placebo, n = 230 | Apremilast 30 mg BID, n = 223 |
|---|---|---|---|
| Age, years, mean (SD) | “49.1 (13.4)” | “49.2 (13.3)” | “47.7 (11.8)” |
| Age group, ≥65 years, n (%) | “61 (13.3)” | “27 (11.7)” | “15 (6.7)” |
| Sex, male, n (%) | “300 (65.4)” | “156 (67.8)” | “152 (68.2)” |
| Race, White, n (%) | “358 (78.0)” | “182 (79.1)” | “177 (79.4)” |
| Race, Asian, n (%) | “68 (14.8)” | “28 (12.2)” | “30 (13.5)” |
| Race, other, n (%) | “33 (7.2)” | “20 (8.7)” | “16 (7.2)” |
| Weight, kg, mean (SD) | “90.4 (24.0)” | “91.0 (24.3)” | “88.9 (21.0)” |
| BMI, kg/m2, mean (SD) | “30.6 (7.2)” | “30.6 (7.2)” | “29.8 (6.5)” |
| Duration of disease, years, mean (SD) | “19.9 (13.5)” | “19.5 (13.3)” | “17.2 (11.8)” |
| PASI, mean (SD) | “20.4 (8.0)” | “19.9 (7.5)” | “20.3 (6.9)” |
| sPGA of 4, n (%) | “129 (28.1)” | “57 (24.8)” | “61 (27.4)” |
| BSA % affected, mean (SD) | “25.8 (15.8)” | “26.2 (16.0)” | “25.2 (14.9)” |
| DLQI, mean (SD) | “10.6 (6.5)” | “10.1 (6.7)” | “10.8 (6.8)” |
| Worst pruritus NRS, mean (SD) | “6.1 (2.7)” | “6.0 (2.7)” | “6.3 (2.6)” |
| Prior systemic psoriasis treatment, n (%) | “221 (48.1)” | “113 (49.1)” | “107 (48.0)” |
Balance across arms and definitions of other race and prior systemic treatment in the ONWARD1 and ONWARD2 baseline table
Baseline itch and scalp involvement by arm in ONWARD1
| Characteristic | Envudeucitinib 40 mg BID, N = 459 | Placebo, N = 230 | Apremilast 30 mg BID, N = 223 |
|---|---|---|---|
| Worst pruritus NRS ≥1, n (%) | “420 (91.5)” | “210 (91.3)” | “210 (94.2)” |
| Worst pruritus NRS ≥4, n (%) | “353 (76.9)” | “175 (76.1)” | “176 (78.9)” |
| ss-PGA ≥3, n | “274” | “135” | “150” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “213 (77.7)” | “102 (75.6)” | “124 (82.7)” |
Baseline characteristics averaged across ONWARD1 and ONWARD2, including prior systemic and prior biologic use
“Data based on average from both studies” (opens the source at this quote in a new tab)
“64 - 67% Male” (opens the source at this quote in a new tab)
“79 - 89% White” (opens the source at this quote in a new tab)
“33 - 38% United States” (opens the source at this quote in a new tab)
“Duration of Psoriasis Diagnosis ~19 years” (opens the source at this quote in a new tab)
“Over 40% prior systemic use” (opens the source at this quote in a new tab)
“Approximately 25% prior biologic use” (opens the source at this quote in a new tab)
“Mean BSA of 26%” (opens the source at this quote in a new tab)
Efficacy results
Co-primary and secondary endpoint results of ONWARD1 and ONWARD2 at topline
PASI 90 and PASI 100 response rates by trial at weeks 16 and 24 in ONWARD1 and ONWARD2
PASI, sPGA, and onset of response in ONWARD1 and ONWARD2 in the congress presentation
Scalp psoriasis response (ss-PGA 0/1) at weeks 4 and 24 in ONWARD1 and ONWARD2
Treat-to-target PASI and BSA thresholds in a post hoc analysis of ONWARD1 and ONWARD2
Efficacy by prior biologic exposure or body weight
No evidence found.
Health-related quality of life and patient-reported outcomes
Quality of life (DLQI 0/1) by week 12 in ONWARD1 and ONWARD2 among participants with baseline DLQI of 2 or more
Mean change in worst pruritus NRS by week 12 and by week 16, and timing relative to PASI 90, in ONWARD1 and ONWARD2
Itch endpoints and methods in the ONWARD1 and ONWARD2 itch analysis
Itch response at week 2, itch resolution at week 16, and responses through week 24 in ONWARD1 and ONWARD2
Safety results
Pooled ONWARD1 and ONWARD2 adverse events through weeks 16 and 24
Deaths, MACE, cytopenias, tuberculosis, laboratory findings, serious infections, and malignancies in pooled ONWARD1 and ONWARD2
Tolerability and most common adverse events in ONWARD1 and ONWARD2 through week 24
Similar adverse event frequency and severity between ONWARD1 and ONWARD2
Herpes zoster and creatine phosphokinase elevations
No evidence found.
Study limitations
Summary
- ONWARD1 results are available from company press releases, a company webcast presentation, and congress materials (Blauvelt et al., Hawkes et al., Ehst et al.). The ClinicalTrials.gov record reads “No Results Posted” and records a certification/extension first submitted on 2026-08-06.
- Placebo control lasted 16 weeks, after which placebo participants rolled over to envudeucitinib; the week 24 PASI results compare envudeucitinib with apremilast alone.
- The report holds no participant disposition by arm, no efficacy by prior biologic exposure or body weight, and no herpes zoster or creatine phosphokinase data. Safety, itch, and DLQI results are reported only for ONWARD1 and ONWARD2 pooled.
- The sources differ on itch: the congress presentation places the mean decrease of more than 4 points in worst pruritus NRS by week 12 and a press release by week 16; at week 16, NRS 0 is reported as over one-third (itch poster) and about 40% (press release), and NRS 0/1 as more than half and approximately 60%.
- Prior treatment is reported on different measures: prior systemic treatment by arm in 221 (48.1%), 113 (49.1%), and 107 (48.0%) participants (congress presentation), and, averaged across both trials, “Over 40% prior systemic use” and approximately 25% prior biologic use (webcast presentation). The report holds no prior biologic use by arm.
- The itch analysis reports nominal P-values, and the PASI and BSA treat-to-target thresholds were calculated post hoc.
- Eligibility excluded participants with lack of clinical response to a TYK2, IL-12, or IL-23 targeted treatment and those with recent or recurrent herpes zoster or herpes simplex infection.
- The webcast presentation lists Belgium among the countries of study ESK-001-016, and the ClinicalTrials.gov API record for NCT06586112 lists Belgium as a removed location country.